硫酸吗啡缓释片联合普瑞巴林治疗癌性神经病性疼痛的疗效及对患者疼痛缓解的影响(1)
【摘要】 目的 分析硫酸嗎啡缓释片联合普瑞巴林治疗癌性神经病性疼痛的疗效及对患者疼痛缓解的影响。方法 102例癌性神经病性疼痛患者， 根据随机数字表法分为对照组及观察组， 各51例。对照组采用硫酸吗啡缓释片治疗， 观察组在对照组基础上联合普瑞巴林治疗。对比两组患者的治疗效果、疼痛程度、睡眠质量和不良反应发生情况。结果 观察组治疗总有效率92.16%高于对照组的76.47%， 差异具有统计学意义 (P<0.05)。治疗后， 两组患者的视觉模拟评分法(VAS)评分均较本组治疗前降低， 且观察组降低程度优于对照组， 差异均具有统计学意义 (P<0.05)。两组患者的睡眠干扰(SLPD)、睡眠量(SLPQ)、睡眠充足度(SLPA)、综合睡眠障碍指数(9-items)评分均较本组治疗前改善， 且观察组改善程度优于对照组， 差异均具有统计学意义 (P<0.05)。观察组不良反应发生率9.80%低于对照组的25.49%， 差异具有统计学意义 (P<0.05)。结论 硫酸吗啡缓释片联合普瑞巴林治疗癌性神经病性疼痛的疗效显著， 能有效缓解患者的疼痛情况， 提高睡眠质量， 降低不良反应发生率， 安全性较高， 值得应用。
【关键词】 癌性神经病性疼痛;硫酸吗啡缓释片;普瑞巴林;疼痛缓解
DOI：10.14163/j.cnki.11-5547/r.2020.12.006
【Abstract】 Objective To analyze the efficacy of morphine sulfate sustained-release tablets combined with pregabalin in the treatment of cancer neuropathic pain and its effect on patients’ pain relief. Methods A total of 102 patients with cancer neuropathic pain were divided into control group and observation group by random number table method， with 51 cases in each group. The control group was treated by morphine sulfate sustained-release tablets， and the observation group was treated by pregabalin on the basis of the control group. The therapeutic effect， pain degree， quality of sleep and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment 92.16% of the observation group was higher than that of the control group 76.47%， and the difference was statistically significant (P<0.05). After treatment， the visual analogue scale (VAS) score of the two groups were lower than those before treatment of the same group， and the degree of reduction of the observation group was better than that of the control group. The difference was statistically significant (P<0.05). The sleep disturbance (SLPD)， sleep quality (SLPQ)， adequacy of sleep (SLPA) and comprehensive sleep disorder index (9-items) scores of the two groups were improved compared with those before treatment， and the improvement degree of the observation group was better than that of the control group. The difference was statistically significant (P<0.05). The incidence of adverse reactions 9.80% of the observation group was lower than that of the control group 25.49%， and the difference was statistically significant (P<0.05). Conclusion Morphine sulfate sustained-release tablets combined with pregabalin shows remarkable efficacy in the treatment of cancer neuropathic pain， and it can effectively relieve the pain of patients， improve sleep quality and lower the incidence of adverse reactions with high safety. It is worthy of application., http://www.100md.com(朱岚 杨宏昕)
【关键词】 癌性神经病性疼痛;硫酸吗啡缓释片;普瑞巴林;疼痛缓解
DOI：10.14163/j.cnki.11-5547/r.2020.12.006
【Abstract】 Objective To analyze the efficacy of morphine sulfate sustained-release tablets combined with pregabalin in the treatment of cancer neuropathic pain and its effect on patients’ pain relief. Methods A total of 102 patients with cancer neuropathic pain were divided into control group and observation group by random number table method， with 51 cases in each group. The control group was treated by morphine sulfate sustained-release tablets， and the observation group was treated by pregabalin on the basis of the control group. The therapeutic effect， pain degree， quality of sleep and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment 92.16% of the observation group was higher than that of the control group 76.47%， and the difference was statistically significant (P<0.05). After treatment， the visual analogue scale (VAS) score of the two groups were lower than those before treatment of the same group， and the degree of reduction of the observation group was better than that of the control group. The difference was statistically significant (P<0.05). The sleep disturbance (SLPD)， sleep quality (SLPQ)， adequacy of sleep (SLPA) and comprehensive sleep disorder index (9-items) scores of the two groups were improved compared with those before treatment， and the improvement degree of the observation group was better than that of the control group. The difference was statistically significant (P<0.05). The incidence of adverse reactions 9.80% of the observation group was lower than that of the control group 25.49%， and the difference was statistically significant (P<0.05). Conclusion Morphine sulfate sustained-release tablets combined with pregabalin shows remarkable efficacy in the treatment of cancer neuropathic pain， and it can effectively relieve the pain of patients， improve sleep quality and lower the incidence of adverse reactions with high safety. It is worthy of application., http://www.100md.com(朱岚 杨宏昕)
参见：首页 > 医疗版 > 症状 > T > 疼痛